Actively Recruiting
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
Led by Ronald Paquette · Updated on 2026-05-07
26
Participants Needed
1
Research Sites
244 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.
CONDITIONS
Official Title
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient age �3E/= 65 years
- Patient and related donor (if applicable) sign the informed consent form for the study
- Patient meets standard criteria for allogeneic stem cell transplant
- Patient is suitable to receive fludarabine and total body irradiation 800 cGy conditioning
- Donor is willing to donate peripheral blood stem cells
You will not qualify if you...
- Diagnosis of myelofibrosis
- High titer antibodies (>10,000 mean fluorescent intensity) against one or more donor HLA antigens
- Prior autologous or allogeneic stem cell transplant
- Requires sedation for cardiac MRI
- Mechanical, magnetic, or electrically activated implants such as pacemakers, neurostimulators, or infusion pumps
- Ferromagnetic implants or foreign bodies like intracranial clips, shrapnel, or metal chips
- Claustrophobia, problems with enclosed spaces, or inability to lie flat
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Actively Recruiting
Research Team
C
Clinical Trials Navigator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here